Menarini Asia-Pacific
Menarini is the world’s largest Italian biopharmaceutical company with a heritage of over 128 years, and more than 16,000 employees in over 100 countries. Here in Asia-Pacific, Menarini’s vision is to be a leading provider of important healthcare brands to improve the lives of people in the region.
See below for the Latest Menarini Asia-Pacific News, Analysis, Profit Results, Share Price Information, and Commentary.
How Menarini Asia Pacific achieves organisational excellence, harnesses agile go-to market approaches
How Menarini Asia Pacific achieves organisational excellence, harnesses agile go-to market approaches
CEO Maurizio Luongo highlights the expansion of the company’s omni-channel distribution strategy beyond traditional pharmaceuticals channels.
Menarini Asia-Pacific bags two awards at the SBR Management Excellence Awards 2022
It was recognised for having a robust team and an outstanding leader that guided the company to success.
Read Here
Advertise
Sign Up
![[Singapore Business Review] Report on the Asian Business Channel](https://www.cmgassets.com/s3fs-public/styles/video_thumbnail/public/2026-10/full-show-thumbnail_1.png.webp?VersionId=bJbrT_JKOuMWBnf7YkmsWjOSWIXddSvY&itok=zWuxHRNG)
Commentary
Singapore’s small exporters need credit that matches their payment cycle
The hidden realities of succession for next-gen heirs
In Asia, fintech leaders must compete on credibility
F1 on a gravel road: Why AI is still stuck in first gear
Why AI blocklists give Singapore firms a false sense of security
When scale arrives before proof: Singapore’s capital allocation question in Southeast Asia
Rethinking fleet ownership in a changing business landscape
Beyond the chips: The materials behind Singapore’s AI infrastructure
How homegrown brands are redefining premium in Asia
AI in hospitality: Where should Singapore’s F&B operators draw the line?